## Analysis of Postpartum Hemorrhage Management ### Correct Statements (Options A, B, D) **Option A: Oxytocin 10 units IM — First-line uterotonic** - Oxytocin is the WHO-recommended first-line uterotonic agent for both prevention and treatment of PPH - For active management of the third stage of labor and initial PPH management, **10 units IM** is the standard recommended dose, particularly in settings where IV access may not be immediately available - IV oxytocin infusion (20–40 units in 500 mL) is used for ongoing management, but the initial IM bolus is the recognized first-line intervention per WHO 2012/2023 guidelines - [cite: WHO Guidelines for the Management of PPH, 2012; Park 26e Ch 25] **Option B: Ergot alkaloids contraindicated in hypertension** - Methylergonovine (ergot alkaloid) causes sustained uterine contraction AND systemic vasoconstriction - Can precipitate hypertensive crisis, myocardial infarction, or stroke in women with pre-existing hypertension, preeclampsia, or eclampsia - Absolutely contraindicated in hypertensive disorders of pregnancy - [cite: KD Tripathi 8e Ch 79] **Option D: Misoprostol preferred without cold chain** - Misoprostol is thermostable and does not require refrigeration, unlike oxytocin - Ideal for resource-limited or low-income settings where cold chain cannot be maintained - Dose: 600 μg sublingually or 800 μg rectally for PPH management - [cite: Park 26e Ch 25; WHO PPH Guidelines] --- ### Incorrect Statement (Option C) — THE ANSWER **"Tranexamic acid should be given within 3 hours of delivery for maximum efficacy" — THIS IS WRONG** **Key Point:** According to the landmark **WOMAN trial (Lancet, 2017)** and current **WHO guidelines**, tranexamic acid (TXA) must be administered **within 1 hour of delivery** (or within 1 hour of onset of PPH) for maximum efficacy in reducing mortality from postpartum hemorrhage. **High-Yield Facts on TXA in PPH:** - **Dose:** 1 g IV over 10 minutes; if bleeding continues after 30 minutes, a second dose of 1 g IV may be given - **Mechanism:** Antifibrinolytic — inhibits plasminogen activation, preventing clot breakdown - **Efficacy window:** Greatest benefit when given within **1 hour**; benefit diminishes significantly after 3 hours (not maximized at 3 hours) - The WOMAN trial showed a **19% reduction in death due to bleeding** when TXA was given within 1 hour vs. 7% reduction at 1–3 hours - After **3 hours**, TXA provides no significant mortality benefit and may increase the risk of thromboembolic events - The **3-hour window** is a classic exam distractor — it represents the outer limit of any possible benefit, NOT the window for maximum efficacy **Clinical Pearl:** The mnemonic: **"TXA — Think eXtra-fast Action"** — give within 1 hour for maximum benefit. The 3-hour figure is sometimes confused with the window for ergot alkaloid use or thrombolytic therapy windows in other contexts. [cite: WOMAN Trial Collaborators, Lancet 2017; WHO Recommendation on TXA for PPH, 2017; Park 26e Ch 25] --- ### Summary Table: Uterotonic Agents in PPH | Agent | Dose | Route | Onset | Contraindications | |---|---|---|---|---| | Oxytocin | 10 units | IM / slow IV | 2–3 min | None absolute | | Methylergonovine | 0.2 mg | IM/IV | 5–10 min | HTN, preeclampsia, CAD | | Misoprostol | 600–800 μg | Sublingual/rectal | 10–15 min | None; heat-stable | | Carboprost | 250 μg | IM | 1–3 min | Asthma, HTN | **Warning:** Confusing the **1-hour TXA window** (maximum efficacy) with the **3-hour outer limit** (beyond which TXA is ineffective) is a classic NEET PG exam trap. Always associate TXA with the 1-hour rule from the WOMAN trial.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.